26-Feb-2021

goetzpartners advised the shareholders on the sale of Sidroga Pharma to Uriach Group

Deal announcement

goetzpartners acted as exclusive M&A advisor to the owners of Germany-based Sidroga Pharma (“the Company”), a leading consumer health group with three umbrella brands for the pharmacy OTC and mass market, for the sale of their shares to Uriach Group, a leading multinational Spain-based pharmaceutical company.

With more than 100 years of experience, Sidroga Pharma is a key market player in the D-A-CH region, distributing respiratory treatment products based on its proprietary natural active pharmaceutical ingredient (API), as well as medicinal teas.

Following Uriach’s growth strategy, Sidroga Pharma constitutes Uriach’s first direct investment in the German speaking countries and provides Uriach access to a highly attractive market with significant synergy potential.

The transaction further underlines goetzpartners’ cross-border M&A competence and adds a remarkable transaction to our healthcare sector expertise. We are pleased by the successful outcome amidst the COVID-19 pandemic.
 

ABOUT SIDROGA PHARMA

With its roots going back to 1858 and headquartered in Bad Ems (Germany), Sidroga Pharma manufactures consumer healthcare products and medicinal teas for pharmacy OTC as well as mass market in the D-A-CH region. Under the historic EMS brand, the Company markets saline-based remedies for the respiratory tract focusing on cough & cold and allergy products. Sidroga stands for market leadership of medicinal tea in the pharmacy channel offering teas and phytopharmaceutical products for various indications. Additionally, EMCUR is the mass market umbrella brand offering respiratory as well as foot fungus products that are distributed via drug stores and food retailers. Sidroga Pharma operates two production sites in Germany with over 150 employees.

ABOUT URIACH

Uriach Group (“Uriach” or “the Company”) is family-owned and one of the oldest pharmaceutical companies in Europe, founded in Barcelona (Spain) in 1838. The Company operates in the B2B as well as consumer health segment. In the B2B segment, Uriach develops active pharmaceutical ingredients (API) and dossiers of generics as well as provides contract manufacturing services for pharmaceuticals, API and food supplements. In the consumer healthcare market, Uriach has a leading position with Aquilea as the umbrella brand for food supplements plus a portfolio of household OTC brands such as Fisiocrem, Cannabix, Halibut, Aero-Red, Biodramina, Utabon and Fave de Fuca. Uriach is active in more than 70 countries worldwide.

TRANSACTION TEAM

Ulrich Kinzel
Managing Director
Email

Matthias Volk
Associate Director

Philipp Jaeck
Associate Director

Moritz Schneider
Analyst